Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
28.75
-0.64 (-2.18%)
At close: Aug 26, 2026, 4:00 PM EDT
28.90
+0.15 (0.52%)
Pre-market: Aug 27, 2026, 7:04 AM EDT
Immunome Employees
Immunome had 247 employees as of June 30, 2026. The number of employees increased by 92 or 59.35% compared to the same quarter last year.
Employees
247
Change
92
Growth
59.35%
Revenue / Employee
n/a
Profits / Employee
-$1,029,648
Market Cap
3.27B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 247 | 92 | 59.35% |
| Mar 31, 2026 | 206 | 75 | 57.25% |
| Dec 31, 2025 | 177 | 59 | 50.00% |
| Sep 30, 2025 | 168 | 63 | 60.00% |
| Jun 30, 2025 | 155 | 77 | 98.72% |
| Mar 31, 2025 | 131 | 69 | 111.29% |
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Sep 30, 2024 | 105 | 50 | 90.91% |
| Jun 30, 2024 | 78 | - | - |
| Mar 31, 2024 | 62 | 25 | 67.57% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| AbCellera Biologics | 562 |
| Tarsus Pharmaceuticals | 370 |
| Arcutis Biotherapeutics | 354 |
| Structure Therapeutics | 281 |
| Alumis | 239 |
| uniQure | 221 |
| Celldex Therapeutics | 198 |
| Disc Medicine | 165 |
IMNM News
- 10 days ago - Immunome price target raised to $35 from $31 at Wedbush - TheFly
- 15 days ago - Immunome reports Q2 EPS (65c), consensus (50c) - TheFly
- 15 days ago - Immunome Reports Second Quarter 2026 Financial Results and Provides Business Update - Business Wire
- 15 days ago - Immunome Earnings release: Q2 2026 - Filings
- 15 days ago - Immunome Quarterly report: Q2 2026 - Filings
- 20 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 5 weeks ago - Immunome announces first patient dosed in Phase 1 IM-3050 trial - TheFly
- 5 weeks ago - Immunome Announces First Patient Dosed in Phase 1 Trial Evaluating IM-3050, an FAP-Targeted Radioligand Therapy, in Patients with FAP-Expressing Advanced Solid Tumors - Business Wire